M2 receptor Inhibitors
1 drugsAbout M2 receptor
The M2 receptor is a muscarinic acetylcholine receptor subtype that plays a crucial role in various physiological processes. As a G protein-coupled receptor (GPCR), it is involved in signal transduction pathways that regulate cellular activity.
The M2 receptor's involvement in airway smooth muscle contraction and mucus secretion makes it a relevant target for respiratory conditions. Currently, there is no genetic evidence directly linking the M2 receptor to specific diseases.
The M2 receptor is targeted by one FDA-approved drug, Tiotropium Bromide, a small molecule used for respiratory conditions. Lupin is the sole company with an approved drug for this target.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Untreated Follicular Lymphoma with only 1 trials.
Top M2 receptor Drugs
Lupin is the only company with an approved drug targeting the M2 receptor.
Low competition suggests easier market entry but also indicates potential challenges in target validation.
M2 receptor Drug Modality Landscape
Modalities
Routes of Administration
M2 receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
The lack of diverse modalities indicates a whitespace opportunity for novel biologics targeting M2.
M2 receptor Clinical Trials 123 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 14 | 12 | 0 | 2 | 100% |
| Phase 2 | 24 | 21 | 3 | 0 | 88% |
| Phase 3 | 44 | 42 | 2 | 0 | 95% |
| Phase 4 | 41 | 38 | 3 | 0 | 93% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M2 receptor Drug Approval Timeline (2012 - 2023)
The first and most recent drug approval for the M2 receptor was Tiotropium Bromide in 2023.
Recent approval suggests renewed interest, but a single approval indicates potential saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 50 clinical trials targeting M2 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities